After being praised by the Technical and Scientific Committee of the Italian Medicines Agency, the National Health Service will reimburse the drug. Ascierto: “Very satisfied”.
Not only vaccines, but also medications to treat people who have coronavirus infections and are at risk of developing severe forms of Covid-19.In the fight against the pandemic, immunosuppressants Tocilizumab Although some studies are not so encouraging, this drug has been used to treat rheumatoid arthritis for many years, although it has already made recommendations for clinical improvement in Covid patients from the beginning.New result Recovery research However, they showed that this medicine Greatly reduced the mortality rate In critically ill hospitalized patients, recovery time is shortened and the need for mechanical ventilation is limited.
In favor of tocilizumab
According to Law No. 648/1996, the Technical and Scientific Committee of the Italian Agency for Medicines (AIFA) considered sufficient efficacy data to include tosizumab in the possible drugs provided by the National Health Service (SSN). Agree) for the treatment of Covid-19.
“AIFA’s reimbursement authorization Used to treat the symptoms of Covid-19 pneumonia -Commented on Paolo Ascierto, an oncologist who is the director of the Medical Oncology and Innovative Therapy Department of the National Cancer Institute of the IRCCS “Pascale” Foundation in Naples, who was the first person to intuitively use anti-arthritis drugs to fight COVID-19- Indicates that the Technical Science Committee has considered the available data on the outcome of rheumatoid arthritis drug treatment for severe patients with coronavirus and agreed to include it in the list Reimbursement of medicines It is regulated by the National Health System (Natural Health System) in accordance with the law. 648, so that patients undergoing treatment do not have to face costs“.
“This -Ascierto summary- For us, this is a great satisfaction and makes us proud, because we persevere and continue to support our opinion from scientific observations: to be the right patient at the right time“.
Tocilizumab blocks the interleukin 6 receptor (IL-6R) (a protein that plays an important role in the immune response), binds to cytokines (interleukin 6) and transduce the activating components of the inflammatory response To play a role. . Therefore, it is believed that the drug can help alleviate the excessive immune response (Cytokine storm) Caused by infection, avoiding some of the more serious complications of the disease.
In the “rehabilitation” study that is currently evaluating multiple potential treatments, more than 36,000 patients have been recruited globally so far. The study randomly assigned 2022 patients to receive tocilizumab treatment and compared their clinical outcomes with those of only 2094 patients receiving standard treatment were compared.In all patients, 82% of patients also received dexamethasone or other systemic steroid hormone therapy, which indicates that combination therapy with tocilizumab can cause Reduce mortality by about one-third It is suitable for patients who need oxygen, and uses nearly half of the oxygen.